A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

NCT02327078 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancies
Colorectal Cancer (CRC)
Head and Neck Cancer
Lung Cancer
Lymphoma
Melanoma
Ovarian Cancer
Glioblastoma

Interventions

DRUG: Nivolumab
DRUG: Epacadostat
DRUG: Chemotherapy

Sponsor

Incyte Corporation

Collaborators

[object Object]